Gene expression profiling of circulating natural killer cells in head and neck squamous cell carcinoma

Cancer Genomics and Proteomics

Volumn 10, Issue 5, 2013, Pages 197-208

  Böttcher, Arne ^a   Ostwald, Jürgen ^b   Koczan, Dirk ^b   Knecht, Rainald ^a   Kramp, Burkhard ^b   Dommerich, Steffen ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cytokine receptors; Gene expression; Gene microarrays; HNSCC; Immune surveillance; Natural killer cells

Indexed keywords

CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; COMPLEMENTARY DNA; CYTOKINE RECEPTOR; FICOLIN; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 7 RECEPTOR; RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HYPOPHARYNX CANCER; IMMUNE SYSTEM; IMMUNOPHENOTYPING; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LARYNX CANCER; MALE; MICROARRAY ANALYSIS; NATURAL KILLER CELL; OROPHARYNX CANCER; SQUAMOUS CELL CARCINOMA; TUMOR IMMUNOLOGY;

CYTOKINE RECEPTORS; GENE EXPRESSION; GENE MICROARRAYS; HNSCC; IMMUNE SURVEILLANCE; NATURAL KILLER CELLS;

ADOLESCENT; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL LINE, TUMOR; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; HEAD AND NECK NEOPLASMS; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84886730586     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
2. Michiels S, Le Maitre A, Buyse M, Burzykowski T, Maillard E, Bogaerts J, Vermorken JB, Budach W, Pajak TF, Ang KK, Bourhis J, Pignon JP; MARCH and MACH-NC Collaborative Groups: Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol 10: 341-350, 2009.
3. Leemans CR, Braakhuis BJ and Brakenhoff RH: The molecular biology of head and neck cancer. Nat Rev Cancer 11: 9-22, 2011.
4. Wittekindt C, Wagner S, Mayer CS and Klussmann JP: Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. Laryngorhinootologie 91(Suppl 1): S1-26, 2012.
5. Burnet FM: The concept of immunological surveillance. Prog Exp Tumor Res 13: 1-27, 1970.
6. Duray A, Demoulin S, Hubert P, Delvenne P and Saussez S: Immune suppression in head and neck cancers: a review. Clin Dev Immunol 2010: 701657, 2010.
7. Agada FO, Alhamarneh O, Stafford ND and Greenman J: Immunotherapy in head and neck cancer: current practice and future possibilities. J Laryngol Otol 123: 19-28, 2009.
8. Whiteside TL: Immunobiology of head and neck cancer. Cancer Metastasis Rev 24: 95-105, 2005.
9. Kross KW, Heimdal JH and Aarstad HJ: Mononuclear phagocytes in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 267: 335-344, 2010.
10. Janjic BM, Lu G, Pimenov A, Whiteside TL, Storkus WJ and Vujanovic NL: Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. J Immunol 168: 1823-1830, 2002.
11. Allen CT, Judd NP, Bui JD and Uppaluri R: The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope 122: 144-157, 2012.
12. Reichert T, DeBruyere M, Deneys V, Tötterman T, Lydyard P, Yuksel F, Chapel H, Jewell D, Van Hove L, Linden J and Buchner L: Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopathol 60: 190-208, 1991.
13. Colucci F, Caligiuri MA and Di Santo JP: What does it take to make a natural killer? Nat Rev Immunol 3: 413-425, 2003.
14. Ferlazzo G and Munz C: NK cell compartments and their activation by dendritic cells. J Immunol 172: 1333-1339, 2004.
15. Vivier E, Tomasello E, Baratin M, Walzer T and Ugolini S: Functions of natural killer cells. Nat Immunol 9: 503-510, 2008.
16. Karre K: Natural killer cell recognition of missing self. Nat Immunol 9: 477-480, 2008.
17. Srivastava S, Lundqvist A and Childs RW: Natural killer cell immunotherapy for cancer: a new hope. Cytotherapy 10: 775-783, 2008.
18. Sutlu T and Alici E: Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 266: 154-181, 2009.
19. Cheng M, Zhang J, Jiang W, Chen Y and Tian Z: Natural killer cell lines in tumor immunotherapy. Front Med 6: 56-66, 2012.
20. Böttcher A, Ostwald J, Guder E, Pau HW, Kramp B and Dommerich S: Distribution of circulating natural killer cells and T lymphocytes in head and neck squamous cell carcinoma. Auris Nasus Larynx 40: 216-221, 2013.
21. Sobin LH, Gospodarowicz MK and Wittekind C: International Union against Cancer. TNM classification of malignant tumours. 7th ed. Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell, 2010.
22. Bose A, Chakraborty T, Chakraborty K, Pal S and Baral R: Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun 8: 10, 2008.
23. Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H and Whiteside TL: Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59: 5356-5364, 1999.
24. Kassouf N and Thornhill MH: Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL and TNF-alpha, to induce apoptosis in Jurkat T cells: possible mechanisms for immune escape by head and neck cancers. Oral Oncol 44: 672-682, 2008.
25. Duffey DC, Chen Z, Dong G, Ondrey FG, Wolf JS, Brown K, Siebenlist U and Van Waes C: Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 59: 3468-3474, 1999.
26. Groth A, Kloss S, von Strandmann EP, Koehl U and Koch J: Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance. J Innate Immun 3: 344-354, 2011.
27. Ostwald J, Dommerich S, Schulz U and Kramp B: Long-term changes in peripheral blood leukocyte and lymphocyte populations in ENT-carcinoma patients. A flow cytometric study in 346 ENT-carcinoma patients and 31 healthy controls. HNO 52: 685-692, 2004.
28. Yoshimura A, Naka T and Kubo M: SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 7: 454-465, 2007.
29. Utreras E, Futatsugi A, Rudrabhatla P, Keller J, Iadarola MJ, Pant HC and Kulkarni AB: Tumor necrosis factor-alpha regulates cyclin-dependent kinase 5 activity during pain signaling through trans-criptional activation of p35. J Biol Chem 284: 2275-2284, 2009.
30. Moncini S, Salvi A, Zuccotti P, Viero G, Quattrone A, Barlati S, De Petro G, Venturin M and Riva P: The role of miR-103 and miR-107 in regulation of CDK5R1 expression and in cellular migration. PLoS One 6: e20038, 2011.
31. Schmitt TM, Ciofani M, Petrie HT and Zuniga-Pflucker JC: Maintenance of T cell specification and differentiation requires recurrent notch receptor-ligand interactions. J Exp Med 200: 469-479, 2004.
32. Jaleco AC, Neves H, Hooijberg E, Gameiro P, Clode N, Haury M, Henrique D and Parreira L: Differential effects of Notch ligands Delta-1 and Jagged-1 in human lymphoid differentiation. J Exp Med 194: 991-1002, 2001.
33. Yang J, Liu X, Nyland SB, Zhang R, Ryland LK, Broeg K, Baab KT, Jarbadan NR, Irby R and Loughran TP Jr.: Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood 115: 51-60, 2010.
34. Dawczynski K, Steinbach D, Wittig S, Pfaffendorf N, Kauf E and Zintl F: Expression of components of the IGF axis in childhood acute myelogenous leukemia. Pediatr Blood Cancer 50: 24-28, 2008.
35. Heesch S, Schlee C, Neumann M, Stroux A, Kühnl A, Schwartz S, Haferlach T, Goekbuget N, Hoelzer D, Thiel E, Hofmann WK and Baldus CD: BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia. Leukemia 24: 1429-1436, 2010.
36. Peschon JJ, Morrissey PJ, Grabstein KH, Ramsdell FJ, Maraskovsky E, Gliniak BC, Park LS, Ziegler SF, Williams DE, Ware CB, Meyer JD and Davison BL: Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 180: 1955-1960, 1994.
37. Puel A, Ziegler SF, Buckley RH and Leonard WJ: Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet 20: 394-397, 1998.
38. Groom JR and Luster AD: CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 89: 207-215, 2011.
39. Hsieh MF, Lai SL, Chen JP, Sung JM, Lin YL, Wu-Hsieh BA, Gerard C, Luster A and Liao F: Both CXCR3 and CXCL10/IFN-inducible protein 10 are required for resistance to primary infection by dengue virus. J Immunol 177: 1855-1863, 2006.
40. Waters CM, Long J, Gorshkova I, Fujiwara Y, Connell M, Belmonte KE, Tigyi G, Natarajan V, Pyne S and Pyne NJ: Cell migration activated by platelet-derived growth factor receptor is blocked by an inverse agonist of the sphingosine 1-phosphate receptor-1. FASEB J 20: 509-511, 2006.
41. Shiue L, Gorman SD and Parnes JR: A second chain of human CD8 is expressed on peripheral blood lymphocytes. J Exp Med 168: 1993-2005, 1988.
42. Ishiyama T, Watanabe K, Fukuchi K, Yajima K, Koike M, Tomoyasu S and Tsuruoka N: The presence of CD5LOW+NK cells in normal controls and patients with pulmonary tuberculosis. Immunol Lett 37: 139-144, 1993.
43. Somanchi SS, Somanchi A, Cooper LJ and Lee DA: Engineering lymph node homing of ex vivo -expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood 119: 5164-5172, 2012.
44. Ye RD and Boulay F: Structure and function of leukocyte chemoattractant receptors. Adv Pharmacol 39: 221-289, 1997.
45. Cheng JF and Jack R: CCR1 antagonists. Mol Divers 12: 17-23, 2008.
46. Zamora C, Canto E, Nieto JC, Angels Ortiz M, Juarez C and Vidal S: Functional consequences of CD36 down-regulation by TLR signals. Cytokine 60: 257-265, 2012.
47. Endo Y, Matsushita M and Fujita T: The role of ficolins in the lectin pathway of innate immunity. Int J Biochem Cell Biol 43: 705-712, 2011.
48. Ihrie RA, Reczek E, Horner JS, Khachatrian L, Sage J, Jacks T and Attardi LD: Perp is a mediator of p53-dependent apoptosis in diverse cell types. Curr Biol 13: 1985-1990, 2003.
49. Beaudry VG, Jiang D, Dusek RL, Park EJ, Knezevich S, Ridd K, Vogel H, Bastian BC and Attardi LD: Loss of the p53/p63 regulated desmosomal protein Perp promotes tumorigenesis. PLoS Genet 6: e1001168, 2010.